Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.
Analysts Set New Price Targets
A number of research firms have commented on TDOC. Cowen downgraded shares of Teladoc Health from an "outperform" rating to a "market perform" rating and cut their target price for the stock from $58.00 to $34.00 in a research report on Tuesday, August 2nd. Robert W. Baird cut their target price on shares of Teladoc Health from $72.00 to $64.00 in a research report on Wednesday, April 27th. Argus downgraded shares of Teladoc Health from a "buy" rating to a "hold" rating in a research report on Thursday, May 5th. Credit Suisse Group downgraded shares of Teladoc Health from an "outperform" rating to a "neutral" rating and cut their target price for the stock from $114.00 to $35.00 in a research report on Thursday, April 28th. Finally, StockNews.com raised shares of Teladoc Health to a "sell" rating in a research report on Tuesday, August 9th. Two analysts have rated the stock with a sell rating, twenty-two have given a hold rating and six have assigned a buy rating to the company. According to data from MarketBeat.com, Teladoc Health has an average rating of "Hold" and a consensus target price of $67.90.
Teladoc Health Price Performance
TDOC Stock traded down $3.50 during mid-day trading on Wednesday, hitting $35.95. The company had a trading volume of 6,607,515 shares, compared to its average volume of 6,250,893. The company has a market capitalization of $5.79 billion, a price-to-earnings ratio of -0.60 and a beta of 0.82. Teladoc Health has a 12-month low of $27.38 and a 12-month high of $156.82. The company has a quick ratio of 3.22, a current ratio of 3.38 and a debt-to-equity ratio of 0.25. The company has a 50-day moving average price of $37.03 and a 200 day moving average price of $50.08.
Insiders Place Their Bets
In other Teladoc Health news, SVP Daniel Trencher sold 1,000 shares of the business's stock in a transaction on Friday, June 17th. The shares were sold at an average price of $29.12, for a total value of $29,120.00. Following the sale, the senior vice president now owns 28,408 shares in the company, valued at approximately $827,240.96. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Mala Murthy sold 4,053 shares of the company's stock in a transaction dated Monday, June 27th. The shares were sold at an average price of $37.32, for a total transaction of $151,257.96. Following the sale, the chief financial officer now directly owns 27,295 shares in the company, valued at approximately $1,018,649.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Daniel Trencher sold 1,000 shares of the company's stock in a transaction dated Friday, June 17th. The shares were sold at an average price of $29.12, for a total transaction of $29,120.00. Following the sale, the senior vice president now owns 28,408 shares in the company, valued at $827,240.96. The disclosure for this sale can be found here. Insiders have sold a total of 6,053 shares of company stock worth $221,498 in the last 90 days. 1.55% of the stock is currently owned by corporate insiders.